Durvalumab: an investigational agent for unresectable hepatocellular carcinoma

Maurizio Pompili, Antonio Gasbarrini, Francesca Romana Ponziani, Marta Maestri, Maria Pallozzi, Francesco Santopaolo, Lucia Cerrito

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Introduction: Programmed death 1 (PD1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte associated protein 4 (CTLA-4) are proteins involved in the modulation of immune response, which are upregulated in hepatocellular carcinoma (HCC) tumor microenvironment (TME). Immune checkpoint inhibitors (ICIs) are a new class of drugs that counteract immunological tolerance to cancer cells. Despite the aggressiveness of HCC and its poor prognosis, only a few tyrosine kinase inhibitors (TKIs) and ICIs have been approved for patients with advanced disease. Areas Covered: We analyze the current knowledge on Durvalumab, a human antibody against PD-L1 its pharmacodynamics, and pharmacokinetics. We provide a description of its application in HCC, illustrating clinical trials that have demonstrated the safety and efficacy in this setting, either as monotherapy or in combination with other ICIs or TKIs, or as adjuvant treatment. Expert Opinion: Durvalumab is a promising drug that could extend the landscape of approved treatments for HCC. The clinical safety profile of Durvalumab was well manageable and comparable to other ICIs, with a low incidence of severe immune-related adverse events (irAEs). The importance of personalized therapy according to tumor characteristics is emerging, but very little is known about factors that could influence the efficacy of ICIs.
Lingua originaleEnglish
pagine (da-a)347-360
Numero di pagine14
RivistaExpert Opinion on Investigational Drugs
Volume31
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • Atezolizumab
  • Bevacizumab
  • CTLA-4
  • Durvalumab
  • HCC
  • tumor microenvironment
  • immune checkpoint inhibitors
  • PD-1
  • PD-L1
  • Tremelimumab
  • HIMALAYA

Fingerprint

Entra nei temi di ricerca di 'Durvalumab: an investigational agent for unresectable hepatocellular carcinoma'. Insieme formano una fingerprint unica.

Cita questo